Al in Drug Development: Opportunities and Challenges

Archana Reddy, MPH, MS Regulatory Affairs

# Overview: Challenges of current development model

#### Time

 Average time from test tube to market is estimated anywhere from 10 years or more (Tufts Center for the Study of Drug Development).

#### Failure Rate

 80 percent or more of potential drug candidates fail in the early phases, leading to large failure rates

#### Costs

 Cost of development of a product from test tube to clinic/patient is estimated to be 2.55 billion (Tufts Center for Study of Drug Development)

# Traditional Model of Clinical Development (FDA)



# Using AI to advance drug discovery

### • Using AI to find insights into a disease

#### • Examples

- Machine learning and deep learning to:
  - Insights and patterns in data pools that can be used to generate hypotheses
  - Examples:
  - IBM Watson used by Pfizer in immuno-oncology research
  - Benevolent AI is using this tool to aid in determining how compounds target certain therapeutic areas

## Al in Discovery and Development: Overview

- Al as a tool is not new, been in existence since the 1980's
- Tool to analyze specific data or large scale data/information to aid in the drug discovery and development process by finding specific targets for specific diseases/therapeutic areas
- Al may be more effective in areas such as immuno-oncology or auto-immune diseases (e.g., identification of the genetic cause)

### Screening and Assessment

- To screen a potential new compound against similar available targets for activity
- To screen compounds in cells or animal models to predict activity
  - Examples
    - Exscientia AI platform to screen compounds in cells or animal models
    - Atomwise to identify potential drug candidates

## Repurposing Existing Drugs

- Finding new uses (e.g., indications) for previously approved drugs using Al
- Already studied or proven drug safety/toxicity profile, so less risk of failure
- Examples
  - IBM Watson and Teva Pharmaceuticals using real world data and mathematical algorithms
  - NuMedii and Astellas Pharma to identify new drug candidates using machine learning

# Use in personalized or precision medicine

- Analysis of individual health data and predictive analysis to identify effective treatment on a patient specific basis
- Application easier than with large scale data and less chance of machine error

#### • Example

• MIT Machine Learning Group to develop deeper understanding of disease process and design drugs

## Challenges in Clinical Development

- Clinical trials fail for a variety of reasons, including failure to recruit enough participants, mid-trail patient drop out, unintended & severe side effects, and poor data collection methods. (CBI Insights, 2018)
- Naturally, trials that fail at a later stage prove more costly for both the company conducting the trial and the patients. (CBI Insights, 2018)

# Al as a tool to aid Clinical Development

- Matching the right trial with the right patient
- 80 % of clinical trials fail to meet enrollment timelines
- 1/3<sup>rd</sup> of Phase 3 early terminations are due to enrollment challenges
  - Potential solution is Electronic Health Records (EHRs) and using AI as a tool to analyze this data to match patients with trials

# Challenges of AI in Clinical Trials

- Concern with data confidentiality and patient privacy with EHRs and AI
- GDPR and the data protection is another concern
- HIPAA and protection of patient data
- Al may not process information in different hospital setting for example in the same way; no standadrization of the data formats etc.

## Conclusion: AI and Development

• Al is potentially a tool for advancing discovery and development however there are a myriad of challenges that need to be overcome before it can be implemented across the board.

## THANK YOU FOR YOUR TIME AND ATTENTION TODAY!